# SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

> **NCT06239480** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Palvella Therapeutics, Inc.** · enrollment: 51 (actual)

## Conditions studied

- Microcystic Lymphatic Malformation

## Interventions

- **DRUG:** QTORIN 3.9% Rapamycin Anhydrous Gel

## Key facts

- **NCT ID:** NCT06239480
- **Lead sponsor:** Palvella Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-31
- **Primary completion:** 2026-01-14
- **Final completion:** 2026-07
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06239480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06239480, "SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06239480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*